Blood Borne Virus Unit Virus Reference Department Centre for Infections HPA Colindale
13
4 July 2022 Blood Borne Virus Unit Virus Reference Department Centre for Infections HPA Colindale Role for HCV antigen detection: a new generation of assays
description
Role for HCV antigen detection: a new generation of assays. Blood Borne Virus Unit Virus Reference Department Centre for Infections HPA Colindale. Samples used for the study. Part 1: 94 acute phase seronegative plasma donors, 51 of which contained detectable RNA - PowerPoint PPT Presentation
Transcript of Blood Borne Virus Unit Virus Reference Department Centre for Infections HPA Colindale
24 April 2023
Blood Borne Virus Unit
Virus Reference Department
Centre for Infections
HPA Colindale
Role for HCV antigen detection: a new generation of assays
Samples used for the study
Part 1: 94 acute phase seronegative plasma donors, 51 of which contained detectable RNAgenotyped, titrated as appropriate
Part 2: Plasma samples from 65 individuals in a randomised clinical trial of Ribavarin/IFNsamples from first 14 days of treatment to assess early dynamics
Part 1 inferences to be drawn:-
• Proficient across limited selection of genotypes 1-3 available
• Linearity also maintained over 3 log10
• Interpolated LOD in range 2-3 log10
Part 2: 300 samples from 65 patients
HCV RNA Viral load log10 iu/ml
HC
V A
g lo
g 10 f
/mol
e
Part 2: Pre- or D3 samples from 59 patients
49 RA
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Base D3 D7 D10 D14 W12
Time
log
HC
V A
g
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
log
HC
V R
NA
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
Base D3 D7 D10 D14 W12
Time
log
HC
V A
g
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
log
HC
V R
NA
64
Time
0.00
0.50
1.00
1.50
2.00
2.50
3.00
BASE D7 D14 W12
log
HC
V A
g
0.00
1.00
2.00
3.00
4.00
5.00
6.00
log
HC
V R
NA
257
0
0.5
1
1.5
2
2.5
3
3.5
4
Base D3 D7 D10 D14 W12
Time
log
HC
V A
g
0
1
2
3
4
5
6
7
log
HC
V R
NA
292
log
HC
V A
g
0
0.5
1
1.5
2
2.5
3
3.5
4
Base D3 D7 D14 W12
0
1
2
3
4
5
6
log
HC
V R
NA
Time
268
Time
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Base D3 D7 D14 W12
log
HC
V A
g
0
1
2
3
4
5
6
7
8
log
HC
V R
NA
Part 2 inferences to be drawn:-
• Good correlation between HCV Ag quantitification and HCV RNA BUT NOT absolute, what is nature of the relationship?
• Response to R/IFN paralleled by both markers• Idiosyncrasies rare but significant, reason?• Qualitative therapy prediction possible early• Need to pin antigenaemia against HCV RNA for each
patient • Positioning- adjunct or alternative?• High risk population or resource-limited sites?
Thanks to:
• Prof Howard Thomas and colleagues for permission to use the “Mild Trial” samples
• Paul Grant, UCL for HCV RNA dataNigel Wallis, Phil Tuke, Siew Lin Ngui and colleagues in BBVU,
VRD
• Abbott Diagnostics for Architect reagents and support
